AC Immune reports interim outcomes from trial of Parkinson’s therapy

AC Immune has reported additional interim safety and positive immunogenicity outcomes from its placebo-controlled Phase II VacSYn trial of anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 for early Parkinson’s disease (PD) treatment.